Lumiracoxib for pain management
Canadian Coordinating Office for Health Technology Assessment
Record ID 32003001144
English, French
Authors' objectives:
To summarize the available information on the use of lumiracoxib (Prexige(TM) from Novartis Pharmaceuticals) for pain management, arthritis, and menstrual cramps.
Authors' results and conclusions:
Clinical data available are sparse, and mostly consist of trials in abstract form. The data available to date suggest that lumiracoxib could be well tolerated.
Authors' recommendations:
To date, there are no data to suggest that lumiracoxib possesses any advantages in terms of efficacy when compared to other NSAIDS. Likewise, it is not possible to say that it has a better gastrointestinal tolerability profile than other well-tolerated NSAIDS already available. Data from the TARGET (Therapeutic Arthritis Research and Gastrointestinal Event Trial) will provide much needed information about the toxicity of this new NSAID relative to naproxen and ibuprofen. These data may also shed more light on the increasingly important issue of the potential harm from drugs with increased COX-2 affinity.
Authors' methods:
Overview
Details
Project Status:
Completed
URL for project:
https://www.ccohta.ca/
Year Published:
2003
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Dysmenorrhea
- Arthritis
- Pain
Contact
Organisation Name:
Canadian Coordinating Office for Health Technology Assessment
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553, Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
Canadian Coordinating Office for Health Technology Assessment (CCOHTA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.